X

Trial Profile

Bioequivalence Randomised, Double-blind, 3-parallel -Group Phase I Study of BFI-751 Compared With EU-STELARA and US-STELARA in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Psoriasis
Focus First in man; Pharmacokinetics; Registrational
Sponsors BioFactura Australia

Most Recent Events

11 Sep 2023 Results presented in the BioFactura Media Release.
11 Sep 2023 According to BioFactura , company announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has entered into an exclusive global license to commercialize BFI-751, BioFactura's proposed biosimilar to Stelara (Ustekinumab).
23 Mar 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com